Rapid Diagnostics Market Performance Outlook 2026–2030: Revenue to Hit $64.78 Billion at 12.4% CAGR

Uncover key drivers, emerging technologies, and competitive movements shaping the rapid diagnostics market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Rapid Diagnostics Market covering 2026–2035?

The rapid diagnostics market has witnessed significant expansion in recent years. It is anticipated to increase from $36.08 billion in 2025 to $40.66 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.7%. The market’s historical growth can be attributed to a heightened demand for quicker clinical diagnostics, the proliferation of decentralized healthcare settings, a rise in the prevalence of chronic and infectious diseases, improved accessibility of diagnostic tools, and the expansion of outpatient diagnostic services.

The rapid diagnostics market is projected to experience substantial growth in the upcoming years. Its valuation is anticipated to reach $64.79 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.4%. This projected growth during the forecast timeframe is primarily driven by factors such as escalating investments in molecular diagnostics, the increasing uptake of connected diagnostic instruments, the broadening availability of home-based testing options, a heightened emphasis on personalized diagnostics, and the expanded application of data-driven clinical workflows. Key developments anticipated within this period encompass the wider utilization of point-of-care diagnostic platforms, the surging adoption of molecular rapid testing, an expanding integration of digital result interpretation, the proliferation of portable diagnostic equipment, and an intensified focus on supporting early clinical decisions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24679&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Rapid Diagnostics Market?

A rising incidence of infectious diseases is anticipated to drive expansion in the rapid diagnostics market moving ahead. Infectious diseases are conditions resulting from harmful microorganisms like bacteria, viruses, parasites, or fungi, capable of transmitting between individuals either directly or indirectly. The heightened occurrence of infectious diseases stems from increased international travel, facilitating quicker transmission and elevated infection rates. Rapid diagnostics are instrumental in managing infectious diseases by providing swift and precise pathogen identification, which supports prompt treatment choices, curtails transmission, and enhances patient results. For illustration, the The World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations focused on international public health, reported in May 2025 that global SARS-CoV-2 (the virus causing COVID-19, an infectious disease) activity had been increasing since mid-February 2025, based on sentinel site data, with the test positivity rate reaching 11%, a figure previously seen in July 2024. Consequently, the expanding incidence of infectious diseases is propelling the rapid diagnostics market.

What Leading Segments Are Studied In The Rapid Diagnostics Market?

The rapid diagnostics market covered in this report is segmented –

1) By Product Type: Kits, Reagents, Instruments, Other Product Types

2) By Platform: Immunoassays, Molecular Detection, Other Rapid Diagnostic Platforms

3) By Application: Blood Glucose Testing, Infectious Disease Testing, Cardiometabolic Testing, Pregnancy and Fertility Testing, Fecal Occult Blood Testing, Coagulation Testing, Toxicology Testing

4) By Distribution Channel: Hospital Pharmacies, Brick and Mortar, E-Commerce, Other Distribution Channels

5) By End Use: Diagnostic Centers, Homecare Settings, Hospital Pharmacies, Other End Users

Subsegments:

1) By Kits: Lateral Flow Assay Kits, PCR Kits, Immunoassay Kits, Microfluidic Kits, Molecular Diagnostic Kits, Multiplex Kits

2) By Reagents: Enzymes, Buffers, Probes and Primers, Stains and Dyes, Antibodies, Calibration and Control Reagents

3) By Instruments: PCR Machines, Lateral Flow Readers, Immunoassay Analyzers, Microfluidic Analyzers, Automated Sample Processors, Biosensors

4) By Other Product Types: Software and Data Management Tools, Sample Collection Devices, Accessories and Consumables, Calibration Standards, Point-of-Care Devices

What Trends Are Expected To Impact The Competitive Landscape Of The Rapid Diagnostics Market?

Major companies in the rapid diagnostics market are concentrating on advancements and innovation, specifically rapid diagnostic testing instruments, to improve diagnostic precision, decrease turnaround times, and enhance patient outcomes in point-of-care settings. Rapid diagnostic testing tools are defined as medical devices that quickly detect the presence of specific diseases or conditions, typically providing results within minutes at the point of care. For example, in May 2025, SEKISUI Diagnostics, a US-based medical diagnostics manufacturer, introduced the OSOM RSV Test, a rapid diagnostic tool designed for identifying respiratory syncytial virus (RSV). This test is intended for use in professional healthcare settings and delivers results in just 15 minutes. It employs a rapid immunochromatographic assay to qualitatively detect RSV nucleoprotein antigen. The test utilizes anterior nasal swab specimens collected from patients exhibiting symptoms of respiratory infection. Its quick turnaround time supports timely and effective clinical decision-making.

Which Key Market Players Are Investing In Expansion And Innovation Within The Rapid Diagnostics Market?

Major companies operating in the rapid diagnostics market are Johnson And Johnson Services Inc, F Hoffmann La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Hologic Inc, bioMerieux SA, QuidelOrtho Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Cepheid Inc, OraSure Technologies Inc, Nova Biomedical Corporation, Fujirebio Holdings Inc, Sekisui Diagnostics LLC, EKF Diagnostics Holdings plc, Trinity Biotech plc, Abingdon Health plc, Abionic SA, LumiraDx Ltd

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/rapid-diagnostics-global-market-report

Which Regions Are Poised For Strategic Growth In The Rapid Diagnostics Market?

North America was the largest region in the rapid diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rapid diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Rapid Diagnostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24679&type=smp

Browse Through More Reports Similar to the Global Rapid Diagnostics Market 2026, By The Business Research Company

Immunochemistry Diagnostic Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunochemistry-diagnostic-devices-and-equipment-global-market-report

Blood Transfusion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report

Hematology Diagnostic Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-diagnostic-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795